Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Czech steam-turbine manufacturer Doosan Skoda Power AS launched an initial public offering, touting an outlook for high ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual ...

Pete Giacchi, Citadel Securities, joins 'Money Movers' to discuss Venture Global's initial public offering, the biggest IPO ...

Venture Global's IPO represents a test for investor appetite for fossil fuel projects in the Trump administration.

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

The listing was a book-built IPO and comprised a fresh issuance of 7.5 million shares. The price band for the issue was Rs ...

In a recent investment round, Bengaluru-based e-commerce platform Meesho received $250–$270 million, with new investors Tiger ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

More generally, markets have a way of recalibrating, and Venture Global’s IPO offers a nuanced lesson. It’s a reminder that valuations aren’t fixed by management or banker decree, but rather hammered ...